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ABSTRACT 
BACKGROUND: In experimental models, thromboxane (Tx)A2 reduced renal perfusion and 
accelerated renal failure. The aim of the study was to investigate the association between the use of 
aspirin, which inhibits TxA2 production, and the incidence of an estimated Glomerular Filtration 
Rate (eGFR) <60 and <45 ml/min/1.73m
2
 in patients with atrial fibrillation (AF) and  chronic 
kidney disease (CKD). 
METHODS: Prospective multicentre observational cohort study including 800 anticoagulated AF 
patients; CKD was defined as an eGFR <90 ml/min/1.73m
2
 by CKD-EPI formula; eGFR was 
measured at baseline and after a median of 28.0 months. Urinary 11-dehydro-TxB2, was measured 
in 401 patients. The incidence of cardiovascular events (CVEs) was also registered. 
RESULTS: Baseline eGFR was 65.1 ml/min/1.73m
2
; 147 and 91 patients had incident eGFR<60 
and <45 ml/min/1.73m
2
, respectively; 16.5% patients received a concomitant treatment with aspirin 
100 mg/day. Multivariate logistic regression analysis showed a direct association with incident 
eGFR<45 ml/min/1.73 m
2
 for female gender (odds ratio [OR]:1.910, p=0.005) and hypertension 
(OR:7.589, p=0.047), while aspirin use was inversely associated (OR:0.347, p=0.016). Propensity 
score adjustment confirmed this association (p=0.017). Patients with incident eGFR<45 
ml/min/1.73m
2
 had higher TxB2, compared to those without (123.0 vs. 90.0 ng/mg creatinine, 
p=0.031); TxB2 was inversely associated with incident eGFR<45 ml/min/1.73m
2
 (log TxB2 OR 
2.239, p=0.036). Incident eGFR<45 ml/min was associated with an increased rate of CVEs 
(HR:2.211, p=0.01). 
CONCLUSION: Aspirin use was associated with a less decline in eGFR in our cohort of AF 
patients with CKD. Our findings suggest that TxA2 may be implicated in renal function 
deterioration in AF. 
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Introduction 
Thromboxane (Tx) A2 is an unstable eicosanoid deriving from arachidonic acid metabolism by 
cyclooxygenase (COX)-1 activation. TxA2 is produced by several cell lines such as platelets, in 
which it acts as aggregating molecule; at level of kidney, its production by glomerular and renal 
artery cells contributes to arterial vasoconstriction[1, 2]. 
Experimental models demonstrated that TxA2 over-production may have a deleterious effect on 
renal function, as inhibition of TxA2 biosynthesis and/or TxA2 receptor antagonism are associated 
with improvement of renal perfusion and a delay of renal insufficiency progression[3-5]. Patients 
with mild to moderate renal failure, i.e. those with creatinine clearance of approximately 50-60 
ml/min/1.73 m
2
, have enhanced production of TxA2 compared to controls[6]. However, it is unclear 
if such over-production is associated with deterioration of renal failure on long-term follow-up. 
Atrial fibrillation (AF) is a common cardiac arrhythmia with a high prevalence in the elderly 
population, typically associated with arterial hypertension and chronic kidney disease (CKD)[7] as 
shown by the REGARDS Study[8]. Moreover, a rapid decline of renal function is associated with a 
higher incidence of cardiovascular outcomes[9]. 
This population is a suitable clinical setting to investigate the role of TxA2 in the progression of 
renal disease, as Tx 2 production in AF patients is associated with progression of vascular disease 
and cardiovascular events[10]. 
Aspirin, which irreversibly acetylates COX1, reduces cardiovascular events (CVEs) in hypertensive 
CKD patients[11]. A dose of aspirin of 50-325 mg/day[12] has been shown to be effective in 
inhibiting TxA2 production[13]. The relationship between TxB2 excretion and in vivo renal 
function, as well as the potential effect of low-dose aspirin on kidney function has never been 
explored in AF. 
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Therefore, we performed a multicentre observational study to assess the relationship between low-
dose (100 mg/day) aspirin treatment and changes in renal function in an elderly AF population 
affected by CKD. 
 
Materials and Methods 
Study design 
Prospective observational multicentre cohort study including 800 non-valvular AF patients affected 
by CKD, defined as a baseline estimated glomerular filtration rate (eGFR) <90 ml/min/1.73 m
2
.  
AF patients were recruited from the Atherothrombosis Centre of I Clinica Medica of “Sapienza” 
University of Rome, from the Department of Medical and Surgical Sciences, University Magna 
Græcia of Catanzaro, Italy), and from the cohort of the Ankle-brachial Index Prevalence 
Assessment: Collaborative Italian Study (ARAPACIS) study[14]. 
All patients were treated with vitamin K antagonists (recommended INR range 2.0-3.0). Exclusion 
criteria were the presence of prosthetic heart valves, chronic infections or autoimmune systemic 
disease, any active cancer or liver insufficiency (eg, cirrhosis), acute ischemic cerebrovascular and 
cardiovascular events in the previous year. At baseline, anthropometric data as well as 
comorbidities and concomitant therapies were collected. Cardiovascular risk factors were defined as 
previously described[10]. 
Definition of renal function 
At baseline, serum creatinine (mg/dl) was obtained for all patients, and eGFR was calculated using 
the 2009 chronic kidney disease epidemiology collaboration (CKD-EPI) formula. Thus, according 
to the CKD-EPI formula, eGFR was adjusted for gender and race. Patients were classified into 
eGFR categories according to the 2013 Kidney disease: improving global outcomes (KDIGO) 
guidelines: normal eGFR (>90 ml/min/1.73 m
2
, Stage G1), mild decrease in eGFR (90-60 
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ml/min/1.73 m
2
, Stage G2), mild to moderate decrease in eGFR (59-45 ml/min/1.73 m
2
, Stage 
G3a), moderate to severe decrease in eGFR (44-30 ml/min/1.73 m
2
, Stage G3b) and severely 
decreased eGFR (<30 ml/min/1.73 m
2
, Stage G4). A second serum creatinine was collected during 
follow-up. 
Primary endpoint 
The study end-point was the incidence of an eGFR <60 and <45 ml/min/1.73 m
2
 during follow-up, 
amongst aspirin users or non-users. 
Secondary endpoint 
As secondary endpoint, we investigated if the incidence of an eGFR <60 and <45 ml/min/1.73 m
2
 
was associated with an increased risk of CVEs during follow-up. The outcome was a composite 
endpoint of MI/cardiac revascularization, ischemic stroke/TIA and cardiovascular death. 
Definitions of CVEs have been previously reported[10]. 
Laboratory analysis 
The analysis of urinary 11-dehydro-TxB2 was performed in a subgroup of 401 AF patients, as in the 
ARAPACIS study and in the Catanzaro cohort, it was not mandatory to collect biological sample at 
baseline. The collection of urine samples was concomitant with the assessment of renal function. 
Excretion of urinary 11-dehydro-TxB2 was measured by an ELISA commercial kit (Cayman). Data 
were expressed as ng/mg urinary creatinine. Intra- and inter-assay coefficients of variation were 
4.0% and 3.6%, respectively. Analyses were performed in a blinded manner. 
Statistical analysis 
Categorical variables were reported as counts (percentage). Continuous variables were expressed as 
mean ± standard deviation or median and interquartile range, as appropriate. Two-sided t tests or 
Wilcoxon rank sum test, depending on the shape of the distribution curve, were used to compare 
means and medians. Pearson chi-square test was used to compare proportions. Bivariate analysis 
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was performed with Pearson's linear correlation. Appropriate nonparametric tests (Mann-Whitney U 
test and Rho Spearman test) were employed for all the other variables. The marginal homogeneity 
test was used for comparison of categorized eGFR classes at baseline and follow-up. To test the 
effect of aspirin on renal function progression, we performed multivariable logistic regression 
analysis, to calculate the adjusted Odds Ratios (OR) of factors associated with the decrease of renal 
function across classes of eGFR, from Stage G1 and G2 to Stage G3a (<60 ml/min/1.73 m
2
) and 
G3b (<45 ml/min/1.73 m
2
). Multivariable analyses were determined with a forward stepwise 
procedure, including all variables that could potentially affect renal function, listed in table 1, with 
the exception for TxB2 and CHA2DS2-VASc score and using hypertension as covariate instead of 
single anti-hypertensive agents. As proof-of-concept, we propensity-score adjusted aspirin effect 
estimates and p-values. The estimated propensity score for aspirin usage was used as a predictor, 
together with aspirin treatment indicator, in multivariable models assessing the relationship with the 
outcomes. The balancing properties of propensity score adjustment have been assessed by 
evaluating the adjusted summaries within each treatment group. As reported in Table 4 after 
propensity score adjustment the two treatment arms are fairly balanced with respect to the 
considered baseline characteristics. Propensity score adjusted estimates can then be expected to be 
close to those that would have been obtained had the treatment been randomized. As secondary 
outcome, we investigated the relationship between incident eGFR <60 and <45 ml/min and the 
occurrence of CVEs during follow-up. The cumulative incidence was estimated using a Kaplan–
Meier product-limit estimator. Survival curves were formally compared using the log-rank test. The 
association with CVEs was analysed separately for the two thresholds of incident eGFR. Cox 
proportional hazards analyses were used to calculate the adjusted relative hazards of CVEs by each 
clinical variable. The multivariable analyses were determined including pre-specified variables 
listed in table 5. 
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All tests were two-tailed and analyses were performed using computer software packages (R v3.0.2, 
R Development Core Team and SPSS-18.0, SPSS Inc.). Only p values <0.05 were considered as 
statistically significant.  
The study was approved by the local ethical board of Sapienza University of Rome (Protocol 
number 593/10). All patients provided written informed consent to participate in the study.  
Results 
Baseline characteristics of 800 AF patients are listed in table 1. Mean age was 73.7±8.4 years, and 
57.6% had paroxysmal AF. Most patients (94.0%) were affected by arterial hypertension; in 
addition, diabetes mellitus was present in 23.0%, heart failure in 18.5%, a history of MI/ CHD and 
Stroke/TIA in 18.6% and 12.5%, respectively (Table 1).   
Median eGFR was 65.1 [52.7-76.4] ml/min/1.73 m
2
. Distribution of eGFR classes at baseline is 
reported in Figure 1. 
One hundred thirty-two (16.5%) AF patients were treated with low-dose of aspirin (100 mg/day), in 
addition to oral anticoagulants. Age, gender, heart failure and history of MI differentiated patients 
with and without aspirin. Conversely, no differences in median baseline eGFR and eGFR classes 
were detected between patients treated or not with aspirin (Table 1). 
A second serum creatinine was obtained at a median of 28.0 [15.2-38.7] months. During follow-up, 
147 patients showed a reduction of eGFR below 60 ml/min/1.73 m
2
, 91 below <45 ml/min/1.73 m
2
, 
and 24 below 30 ml/min/1.73 m
2
. Marginal homogeneity test showed a significant change in eGFR 
classes distribution at follow-up (Figure 1, p<0.001). 
Table 2 shows demographic and clinical characteristics of patients with incident eGFR<60 
ml/min/1.73 m
2
. At multivariable logistic regression analysis, age and arterial hypertension were 
significantly associated with incident eGFR <60 ml/min/1.73 m
2
, while aspirin use showed no 
effect (Table 3, Panel A). 
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Patients with decline of eGFR <45 ml/min/1.73 m
2
 were older, with a higher CHA2DS2-VASc 
Score, more frequently women, hypertensive and less treated with aspirin (Table 2), compared to 
patients with stable eGFR. Multivariate logistic regression analysis (Table 3, Panel B), showed a 
direct association with incident eGFR <45 ml/min/1.73 m
2
 for female gender and arterial 
hypertension, while aspirin use was inversely associated. 
Our findings were confirmed after propensity score adjustment (Table 4). Thus, aspirin use was 
inversely associated with incident eGFR <45 ml/min/1.73 m
2
 (OR: 0.352, 95% CI 0.133-0.771, 
p=0.017), but not with incident eGFR <60 ml/min/1.73 m
2
 (OR: 0.908, 95% CI 0.526-1.526, 
p=0.722). 
Renal function and cardiovascular events 
During follow-up, 70 CVEs were recorded. Aspirin use was not associated with CVEs in the whole 
cohort (log-rank test, p=0.368). No association was found between incident eGFR <60 ml/min and 
CVEs (not shown). CVEs occurred in 16/91 and 43/599 patients with and without incident eGFR 
<45 ml/min, respectively.  
Incident eGFR <45 ml/min was associated with a significant increased rate of CVEs (log-rank test 
p=0.009), and at univariate Cox regression analysis, (HR: 2.11, 95%CI 1.19-3.76, p=0.011) was 
predictive of CVEs. This association remained significant at multivariable analysis (Table 5).  
Analysis of urinary excretion of Thromboxane B2 
In a subgroup of 401 AF patients, in whom urine sample was collected, we measured baseline 
urinary excretion of TxB2. In this group, median TxB2 was 98.0 [55.0-162.5] ng/mg creatinine, 
while median eGFR was 64.4 [52.1-75.2] ml/min/1.73 m
2
. At baseline, 247 (61.6%) AF patients 
had an eGFR between 90-60 ml/min/1.73 m
2
, 97 (24.2%) between 59-45 ml/min/1.73 m
2
, 43 
(10.7%) between 44-30 ml/min/1.73 m
2
, and 14 (3.5%) below 30 ml/min/1.73 m
2
, similar to those 
of the entire population. 
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We found no difference in TxB2 levels in patients with (n=95, median TxB2 90.0 [50.0-180.0]) and 
without (n=152, median TxB2 98.0 [50.5-180.0]) incident eGFR<60 ml/min/1.73 m
2
 (p=0.573). 
Conversely, TxB2 was higher in patients with incident eGFR <45 ml/min/1.73 m
2 
(n=63, median 
TxB2 123.0 [68.0-257.0]), compared to those without incident eGFR <45 ml/min/1.73 m
2
 (n=280, 
median TxB2 90.0 [50.5-160.0], p=0.031, Figure 2). Among the 401 patients 48 were aspirin users; 
they had significantly lower levels of TxB2 (median TxB2 72.5 [45.0-120.0] compared to those 
aspirin-free (n=353, median TxB2 100.0 [60.0-175.5], p=0.014).  
Univariate logistic regression analysis confirmed that TxB2 levels were significantly associated with 
incident eGFR<45 ml/min/1.73 m
2
 (log TxB2 OR 2.239, 95%CI 1.056-4.747, p=0.036), with no 
interaction with the use of aspirin (p=0.5122), suggesting that the negative association between 
TxB2 and renal function is similar in aspirin users and non-users. Log- TxB2 was significantly 
associated with CVEs (n=47, HR: 1.86, 95%CI 1.30-2.65, p=0.001). 
Discussion and conclusions 
This study provides the first evidence that in patients with AF, the use of aspirin was associated 
with a less decline of renal function, and suggests that TxA2 plays a role in the progression of renal 
failure. 
Prior studies investigated the relationship between TxA2 and renal function in patients with renal 
disease showing that the balance of prostacyclin/TxA2 is crucial for an optimal renal function[15]. 
In particular, an inverse association between biosynthesis of prostacyclin, which is a vasodilator 
molecule, and creatinine clearance was detected in patients with chronic glomerular disease[15]. 
Furthermore, in patients with lupus nephritis, the acute infusion of a selective thromboxane receptor 
antagonist resulted in an increased renal clearance[5]. Similar finding was observed in patients with 
heart failure treated with picotamide, a dual antiplatelet molecule inhibiting TxA2 synthase and 
acting as TxA2 receptor antagonist[16]. Thus, patients given picotamide for 8 days showed an 
improvement of renal flow and glomerular filtration rate along with a decrease of vascular 
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resistance compared to placebo suggesting that inhibiting TxA2 synthase or activity improves renal 
function by interfering with renal perfusion[4]. While these data are in favor of a role of TxA2 as 
molecule associated with worsening renal function, few prospective data exist on the relationship 
between TxA2 and renal function on a long-term follow-up.  
In this study, we focused on patients with AF, a condition that is associated with CKD[8]. For 
instance, Roldàn et al[17]  found a moderate renal impairment in 28% out of 978 patients affected 
by AF[17], with a reduction in the eGFR ≥10 ml/min in 21% of patients after 2 years. 
In our cohort of AF patients with CKD, we found that an incident eGFR <60, <45 and <30 ml/min 
were detected in 18%, 11% and 3%, respectively, with age, female gender and arterial hypertension 
significantly associated with a decline in the renal function.  
The fact that most of our AF patients were hypertensive is in keep with the work by Roldàn et 
al[17] in which 82% of AF patients were hypertensive, and reinforces the role of arterial 
hypertension as risk factor for AF[18] and CKD[19]. 
Similarly to previous reports[17], approximately 17% of our AF population was on treatment with 
aspirin. The prevalence of heart failure and previous cardiovascular event was higher in aspirin 
users, suggesting that physicians tend to associate oral anticoagulants to antiplatelet drugs  after an 
acute cardiovascular event. 
 One novel finding of the present study is the significant association between aspirin use and delay 
in renal function progression. In particular, aspirin use was associated with lower incident eGFR 
<45 ml/min, while no association has been found with incident eGFR <60ml/min. 
When we analysed the relationship between baseline urinary excretion of TxB2, which is a reliable 
marker of TxA2 biosynthesis, and renal function deterioration, we found that patients with incident 
eGFR <45ml/min had significantly higher urinary excretion of TxB2 compared with those with 
values >45 ml/min providing indirect evidence on a TxA2 role in progression to moderate-severe 
renal failure. 
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The study has implications and limitations. Previous study demonstrated that patients with 
hypertension have enhanced production of TxB2[20], but it has never been investigated if 
hypertension elicits renal dysfunction also via TxB2 over-production. As >90% of our patients were 
hypertensive, it is possible that aspirin delays renal dysfunction by blunting hypertension-related 
TxB2 over-production. 
The study has been done in an elderly population with AF and therefore, results cannot be 
extrapolated to other settings affected by chronic renal disease. Moreover, as all patients included in 
the study were Caucasian, these data cannot be generalized to other ethnic groups. The lack of 
randomization is an intrinsic limitation of the study, although propensity-adjusted analysis 
confirmed our findings. Finally, a limitation of the study is in a relatively low number of patients in 
G3b stage. 
In conclusion, the study provides evidence that aspirin use is associated with a delay in the renal 
function deterioration in AF patients, suggesting TxA2 as a molecule favouring progression of renal 
disease. This finding may represent a valid rationale for planning interventional trials with aspirin 
or TxA2 receptor antagonist in this setting. 
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Figure legends 
Figure 1. Sequential changes in eGFR classes distribution during follow-up compared to 
baseline.  
Figure 2. Median value of urinary excretion of 11-dehydro-TxB2 in the all cohort (left 
column), and in patients with (middle column) and without (right column) incident eGFR <45 
ml/min/ 1.73 m
2
. 
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Table 1. Baseline characteristics of AF cohort overall, and according to the use of aspirin. 
 Overall 
(n=800) 
Aspirin use  
 No (n=668)          Yes (n=132) 
p 
Age (years) 73.7±8.4 74.1±8.3 71.9±8.5 0.008 
Paroxysmal AF (%) 57.6 58.1 55.3 0.564 
Women (%) 46.0 47.9 36.4 0.017 
Body Mass Index (kg/m
2
) 27.7±4.6 27.6±4.6 28.1±4.6 0.323 
Baseline eGFR (ml/min/1,73m
2
)
 
#
 
65.1 
[52.7-76.4] 
64.8  
[52.7-76.1] 
67.4  
[54.2-80.0] 
0.211 
eGFR classes distribution (%)    0.248 
G2 62.6 61.8 66.7  
G3a 23.9 25.1 17.4  
G3b 10.4 9.9 12.9  
G4 3.1 3.1 3.0  
CHA2DS2-VASc Score
#
 4.0 [3.0-4.0]
 
 4.0 [3.0-4.0] 4.0 [2.0-5.0] 0.227 
Arterial Hypertension (%) 94.0 93.6 96.2 0.316 
ACE inhibitors/ARBs (%) 73.5 71.3 84.8 0.001 
β blockers (%) 49.1 49.6 47.0 0.634 
Calcium channel antagonists 
(%) 
28.1 29.2 22.7 0.139 
Diabetes mellitus (%) 23.0 22.0 28.0 0.142 
History of MI/ CHD (%) 18.6 15.9 32.6 <0.001 
Heart Failure (%) 18.5 17.2 25.0 0.049 
History of Stroke/TIA (%) 12.5 12.6 12.1 0.885 
Aspirin (%) 16.5 - - - 
Statins (%) 45.0 44.0 50.0 0.214 
Thromboxane B2 (ng/mg 
creatinine)* 
98.0 [55.0-
162.5] 
100.0 [60.0-
175.5] 
72.5 [45.0-
120.0] 
0.014 
#
data expressed as median and interquartile range; *data in 401 AF patients 
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ACE: angiotensin converting enzyme, ARBs: angiotensin receptor blockers, CHD: coronary heart 
disease, eGFR: estimated glomerular filtration rate, MI: myocardial infarction, TIA: transient 
ischemic attack. 
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Table 2. Demographic and clinical characteristics of patients with incident eGFR <60 and <45 ml/min/1.73 m
2
.  
 Incident eGFR <60 ml/min/1.73 m
2
 
       No (n=351)            Yes (=147) 
p Incident eGFR <45 ml/min/1.73 m
2
 
No (n=599)            Yes (=91) 
p 
Age (years) 71.2±8.5 73.4±8.1 0.006 72.8±8.6 75.2±6.6 0.002 
Women (%) 38.2 49.0 0.028 42.4 59.3 0.003 
Body Mass Index (kg/m
2
) 28.0±4.6 27.5±4.5 0.277 27.8±4.6 27.7±4.6 0.885 
Paroxysmal AF (%) 57.5 56.5 0.843 57.1 56.0 0.910 
CHA2DS2-VASc Score
#
 3.0 [2.0-4.0] 3.0 [2.0-4.0] 0.656 3.0 [2.0-4.0] 4.0 [3.0-5.0] 0.027 
Arterial Hypertension (%) 90.9 96.6 0.025 92.7 98.9 0.021 
Diabetes mellitus (%) 23.1 17.7 0.191 22.7 23.1 0.937 
History of MI/ CHD (%) 17.4 16.3 0.896 17.9 20.9 0.469 
Heart Failure (%) 17.9 10.2 0.031 17.5 18.7 0.769 
History of Stroke/TIA (%) 12.0 12.9 0.766 13.0 12.1 0.804 
Aspirin (%) 18.5 15.6 0.520 17.5 6.6 0.006 
Statins (%) 43.0 44.2 0.843 44.4 53.8 0.113 
Thromboxane B2 (ng/mg creatinine)* 98.0 [50.5-180.0] 90.0 [50.0-180.0] 0.573 90.0 [50.0-160.0] 123.0 [68.0-257.0] 0.031 
#
data expressed as median and interquartile range; *data on 247 AF patients for incident 60 ml/min, and on 343 for incident 45 ml/min. 
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AF: atrial fibrillation, CHD: coronary heart disease, eGFR: estimated glomerular filtration rate, MI: myocardial infarction, TIA: transient ischemic 
attack. 
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Table 3. Stepwise multivariable logistic regression analysis of factors associated with incident 
eGFR <60 ml/min/1.73 m
2
 (Panel A) and <45 ml/min/1.73 m
2
 (Panel B).  
 
Panel A p OR 95% CI 
Age 0.008 1.034 1.009-1.061 
Arterial Hypertension 0.040 2.783 1.050-7.381 
After adjustment for female gender, diabetes, heart failure, history of Stroke/TIA, history of 
MI/CHD, aspirin, statins and body mass index, type of AF (paroxysmal vs. persistent/permanent 
AF) 
Panel B p OR 95% CI 
Female gender 0.005 1.910 1.214-3.005 
Arterial Hypertension 0.047 7.589 1.029-55.982 
Aspirin 0.016 0.347 0.147-0.819 
After adjustment for age, diabetes, heart failure, history of Stroke/TIA, history of MI/CHD, statins 
and body mass index, type of AF (paroxysmal vs. persistent/permanent AF) 
AF: atrial fibrillation, CHD: coronary heart disease, eGFR: Estimated Glomerular Filtration Rate, 
MI: myocardial infarction, TIA: transient ischemic attack. 
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Table 4. Baseline characteristics of AF cohort with baseline eGFR>60 (Panel A) and >45 
(Panel B) ml/min/1.73 m
2
, according to the use of aspirin after propensity score adjustment. A 
standardized difference (SD) < 10% indicates balance of the two groups after adjustment.  
Panel A Aspirin use  SD 
No Yes 
Age (years) 55.7±7.4 55.8±7.4 0.018 
Women (%) 1.6 1.6 0.042 
Body Mass Index (kg/m
2
) 29.4±4.6 29.4±4.6 0.009 
Paroxysmal AF (%) 51.1 51.2 0.002 
Arterial Hypertension (%) 99.9 99.9 <0.001 
Diabetes mellitus (%) 37.9 37.9 <0.001 
History of MI/ CHD (%) 99.8 99.8 <0.001 
Heart Failure (%) 97.6 97.8 0.003 
History of Stroke/TIA (%) 13.9 14.1 0.014 
Statins (%) 92.1 92.0 <0.001 
Panel B Aspirin use  SD 
No Yes 
Age (years) 57.3±7.1 57.4±7.1 0.018 
Women (%) 1.0 1.0 0.001 
Body Mass Index (kg/m
2
) 31.6±4.5 31.5±4.5 0.014 
Paroxysmal AF (%) 53.9 54.1 0.004 
Arterial Hypertension (%) 99.9 99.9 <0.001 
Diabetes mellitus (%) 37.3 37.2 0.001 
History of MI/ CHD (%) 99.8 99.8 0.001 
Heart Failure (%) 85.2 85.7 0.006 
History of Stroke/TIA (%) 16.3 16.6 0.018 
Statins (%) 73.6 73.8 0.003 
AF: atrial fibrillation, CHD: coronary heart disease, eGFR: Estimated Glomerular Filtration 
Rate, MI: myocardial infarction, SD: Standardized Difference, TIA: transient ischemic 
attack. 
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Table 5. Adjusted hazard ratios for cardiovascular events by Cox proportional hazards model 
according to selected variables. 
 
 Hazard 
Ratio 
95% Confidence 
Interval 
p 
Paroxysmal AF (vs. 
persistent/permanent) 
0.782 0.460 1.329 0.364 
Female gender 0.772 0.447 1.334 0.354 
Age 1.069 1.026 1.113 0.001 
Diabetes 1.701 0.961 3.012 0.068 
Heart failure 1.372 0.713 2.643 0.344 
Previous stroke/TIA 1.772 0.902 3.480 0.097 
Previous MI/CHD 2.070 1.165 3.676 0.013 
Antiplatelet 1.126 0.575 2.205 0.728 
Arterial ypertension 0.432 0.128 1.463 0.178 
Statin 1.117 0.655 1.906 0.684 
Body mass index 1.008 0.950 1.070 0.792 
Incident eGFR <45 ml/min 2.211 1.207 4.048 0.010 
 
AF: atrial fibrillation, CHD: coronary heart disease, eGFR: estimated glomerular filtration rate, MI: 
myocardial infarction, TIA: transient ischemic attack. 
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